文献速递乳腺癌头颈与中枢神经肿瘤

曲妥珠单抗鞘内注射治疗HER2阳性乳腺癌脑膜转移的I期可行性研究

Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
PubMed 文献 · Eur J Cancer · 2018-04-07

未观察到剂量限制性毒性,150 mg剂量组脑脊液平均残留浓度为27.9 mg/L,最大耐受剂量及推荐II期 weekly 剂量为150 mg。

要点

  • 未观察到鞘内曲妥珠单抗的剂量限制性毒性,安全性可接受
  • 150 mg剂量组脑脊液平均残留浓度为27.9 mg/L
  • 最大耐受剂量及推荐II期每周剂量为150 mg

核心结论

  • 鞘内注射曲妥珠单抗在HER2阳性乳腺癌脑膜转移患者中未观察到剂量限制性毒性,最大耐受剂量及推荐II期每周剂量为150 mg。

主要发现

  • 60 mg及以上剂量组中,归因于鞘内曲妥珠单抗的轻微毒性包括头痛2例、恶心2例、呕吐1例、颈部疼痛1例及周围神经病变1例。
  • 2例患者出现即刻毒性,包括头痛或呕吐。
  • 150 mg剂量组脑脊液曲妥珠单抗平均残留浓度为27.9 mg/L。
  • 3例患者达临床缓解,7例疾病稳定,4例疾病进展。

关键数值与推荐

  • 最大耐受剂量及推荐II期每周剂量为150 mg。
  • 150 mg剂量组脑脊液曲妥珠单抗平均残留浓度为27.9 mg/L。

临床怎么用

  • 对于HER2阳性乳腺癌脑膜转移患者,可考虑每周鞘内注射曲妥珠单抗150 mg,但需在临床试验框架下使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Leptomeningeal carcinomatosis (MC) is commonly associated with HER2-positive breast cancer (HER2-BC), with a poor prognosis and no standardised treatment. We conducted a phase I dose-escalation study of intrathecal (IT) administration of trastuzumab in HER2-BC patients with MC to determine the maximum tolerated dose (MTD), which was based on both the achievement of a trastuzumab intra-cerebrospinal fluid concentration close to a conventional therapeutic plasma concentration (30 mg/L) and/or dose-limiting toxicity (DLT). METHODS: The protocol planned IT administration of trastuzumab (30 mg, 60 mg, 100 mg or 150 mg dose levels) once a week, over the course of at least 4 weeks. Sixteen patients with MC from HER2-BC received IT trastuzumab. Intra-cerebrospinal fluid samples were obtained before each injection for pharmacokinetics. RESULTS: We did not observe DLT of IT trastuzumab. Eleven patients had no toxicity attributed to IT trastuzumab. For 60 mg or higher dose levels, minor toxicities attributed to IT trastuzumab included headache (2 patients), nausea (2 patients), vomiting (1 patient), cervical pain (1 patient) and peripheral neuropathy (1 patient). Two patients experienced immediate toxicity including headache or vomiting. The mean residual intra-cerebrospinal fluid concentration of trastuzumab was 27.9 mg/L for the 150 mg dose level. Three patients achieved a clinical response, seven patients had stable disease and four patients had progressive disease. CONCLUSIONS: The MTD and recommended phase II weekly dose of IT trastuzumab in patients with HER2-BC and MC is 150 mg. A phase II trial using this dose regimen in MC from HER2-BC is ongoing. REGISTRATION IDENTIFICATION: ClinicalTrials.gov Identifier: NCT01373710 (https://clinicaltrials.gov/ct2/show/NCT01373710?term=trastuzumab+intrathecal&rank=1).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bonneau C, Paintaud G, Trédan O, et al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer. 2018. PMID: 29635147. doi:10.1016/j.ejca.2018.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。